RUNX1 gene mutation in primary myelodysplastic syndrome – the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Summary: Mutations of Runt‐related transcription factor 1 (RUNX1) have been detected in patients with myelodysplastic syndrome (MDS). However, the prognostic implication of RUNX1 mutations in primary MDS is limited. The stage of the disease at which the mutations are acquired and whether they persist during the disease course also remain unclear. We analysed mutations of RUNX1 exons 3–8 in 132 patients with primary MDS and correlated the results with clinical features. Serial studies were performed during the follow‐up period. Sixteen patients (12%) had RUNX1 mutations at the time of diagnosis. All RUNX1 mutations that were detected at diagnosis remained unchanged during the clinical course. Two other patients acquired RUNX1 mutations at leukaemic transformation 34 months and 35 months after the diagnosis of MDS. Patients with RUNX1 mutations at diagnosis had higher neutrophil counts and higher frequency of −7/7q deletion than those without. Furthermore, RUNX1 mutation was closely associated with a short overall survival (P = 0·039). This is the first report to demonstrate that RUNX1 mutation can not only be detected early at diagnosis but also acquired during disease progression and is associated with poor prognosis in patients with primary MDS. It may play a role in the development and progression of a subset of primary MDS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ichikawa, M., Asai, T., Saito, T., Yamamoto, G., Seo, S., Yamazaki, I., Yamagata, T., Mitani, K., Chiba, S., Hirai, H., et al. (2004) · Nature Medicine · doi:10.1038/nm997 · Cited by 596 · cited 1×
“…subunit of the heterodimeric CBF complex, which is essential for the development of definitive haematopoiesis (Speck & Gilliland, 2002; de Bruijn & Speck, 2004) Homozygous Runx1 knockout mice die in utero because of impaired haematopoiesis (Higuchi et al, 2002; Ichikawa et al, 2004).”
BackgroundHarada, H., Harada, Y., Niimi, H., Kyo, T., Kimura, A., & Inaba, T. (2004) · Blood · doi:10.1182/blood-2003-09-3074 · Cited by 281
Preudhomme, C., Warot-Loze, D., Roumier, C., Grardel-Duflos, N., Garand, R., Lai, J. L., Dastugue, N., Macintyre, E., Denis, C., Bauters, F., et al. (2000) · Blood · doi:10.1182/blood.v96.8.2862 · Cited by 263
Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2004) · Blood · doi:10.1182/blood-2004-02-0754 · Cited by 135 · cited 7×
“Recently, RUNX1 mutations have been reported in patients with MDS, especially that secondary to atomic-bomb radiation or therapy (Imai et al, 2000; Preudhomme et al, 2000; Harada et al, 2003, 2004; Christiansen et al, 2004; Nakao et al, 2004; Osato, 2004; Steensma et al, 2005; Niimi et al, 2006).”
BackgroundResultInfluentialNiimi, H., Harada, H., Harada, Y., Ding, Y., Imagawa, J., Inaba, T., Kyo, T., & Kimura, A. (2006) · Leukemia · doi:10.1038/sj.leu.2404136 · Cited by 69 · cited 11×
“Recently, RUNX1 mutations have been reported in patients with MDS, especially that secondary to atomic-bomb radiation or therapy (Imai et al, 2000; Preudhomme et al, 2000; Harada et al, 2003, 2004; Christiansen et al, 2004; Nakao et al, 2004; Osato, 2004; Steensma et al, 2005; Niimi et al, 2006).”
BackgroundInfluentialNakao, M., Horiike, S., Fukushima‐Nakase, Y., Nishimura, M., Fujita, Y., Taniwaki, M., & Okuda, T. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04966.x · Cited by 34 · cited 15×
“Recently, RUNX1 mutations have been reported in patients with MDS, especially that secondary to atomic-bomb radiation or therapy (Imai et al, 2000; Preudhomme et al, 2000; Harada et al, 2003, 2004; Christiansen et al, 2004; Nakao et al, 2004; Osato, 2004; Steensma et al, 2005; Niimi et al, 2006).”
Influential
Cited by
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627
Clonal Architecture of Secondary Acute Myeloid Leukemia
Walter, M. J., Shen, D., Ding, L., Shao, J., Koboldt, D. C., Chen, K., Larson, D. E., McLellan, M. D., Dooling, D., Abbott, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106968 · Cited by 775
Malcovati, L., Hellström-Lindberg, E., Bowen, D., Adès, L., Cermak, J., del Cañizo, C., Della Porta, M. G., Fenaux, P., Gattermann, N., Germing, U., et al. (2013) · Blood · doi:10.1182/blood-2013-03-492884 · Cited by 669
Role of RUNX1 in hematological malignancies
Sood, R., Kamikubo, Y., & Liu, P. (2017) · Blood · doi:10.1182/blood-2016-10-687830 · Cited by 494
Tang, J.-L., Hou, H.-A., Chen, C.-Y., Liu, C.-Y., Chou, W.-C., Tseng, M.-H., Huang, C.-F., Lee, F.-Y., Liu, M.-C., Yao, M., et al. (2009) · Blood · doi:10.1182/blood-2009-05-223784 · Cited by 344
Self-citation
Metadata
- Authors
- Chen, C., Lin, L., Tang, J., Ko, B., Tsay, W., Chou, W., Yao, M., Wu, S., Tseng, M., & Tien, H.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2007-10
- Volume
- 139
- Issue
- 3
- Pages
- 405-414
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W1489375841
- Cited by
- 134
- References
- 6
- FWCI
- 4.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RUNX1 gene mutation in primary myelodysplastic syndrome – the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. https://app.cochat.ai/papers/10.1111/j.1365-2141.2007.06811.x
- The paper
- Chen, C., Lin, L., Tang, J., Ko, B., Tsay, W., Chou, W., Yao, M., Wu, S., Tseng, M., & Tien, H. (2007). RUNX1 gene mutation in primary myelodysplastic syndrome – the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2007.06811.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.